XERS fundamentals
Xeris Biopharma Holdings, Inc. revenue breakdown overview
Xeris Biopharma Holdings, Inc. revenue for the last year amounted to 196.64 M USD, the most of which — 196.64 M USD — came from its highest performing source at the moment, Gvoke, Keveyis and Recorlev, the year earlier bringing 153.36 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Xeris Biopharma Holdings, Inc. 203.07 M USD, and the year before that — 163.91 M USD.
By source
2017
2018
2019
2020
2021
2022
2023
2024
0.00
55.00 M
110.00 M
165.00 M
220.00 M
Gvoke, Keveyis and Recorlev
Royalty, Contract and Other
Service
Currency: USD
2017
2018
2019
2020
2021
2022
2023
2024
Gvoke, Keveyis and Recorlev
20.16 M
49.28 M
109.26 M
153.36 M
196.64 M
Royalty, Contract and Other
280.00 K
310.00 K
985.00 K
10.55 M
6.43 M
Service
—
—
—
—
—
By country
2017
2018
2019
2020
2021
2022
2023
2024
0.00
55.00 M
110.00 M
165.00 M
220.00 M
United States
Currency: USD
2017
2018
2019
2020
2021
2022
2023
2024
United States
20.43 M
49.59 M
110.25 M
163.91 M
203.07 M